Automated brain tumor biopsy prediction using single-labeling cDNA microarrays-based gene expression profiling

Diagnostic Molecular Pathology

Volumn 18, Issue 4, 2009, Pages 206-218

  Castells, Xavier ^a,b   García Gómez, Juan Miguel ^c   Navarro, Alfredo ^c   Acebes, Juan José ^b,c   Godino, Óscar ^b,c   Boluda, Susana ^a   Barceló, Anna ^b,d   Robles, Montserrat ^c   Ariño, Joaquín ^b,d   Arús, Carles ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITAT POLITÈCNICA DE VALÈNCIA   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

Automated; Brain tumor; CDNA microarrays

Indexed keywords

COMPLEMENTARY DNA; CYTOCHROME; LIQUID NITROGEN; RNA;

ARTICLE; BRAIN BIOPSY; CELL ADHESION; CLINICAL FEATURE; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE LOCUS; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MOLECULAR CLONING; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; TUMOR CLASSIFICATION;

AUTOMATION, LABORATORY; BIOPSY; BRAIN NEOPLASMS; DNA, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MENINGEAL NEOPLASMS; MENINGIOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM;

EID: 74749084161     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/PDM.0b013e31818f071b     Document Type: Article

References (69)

1. Oliver TG, Wechsler-Reya RJ. Getting at the root and stem of brain tumors. Neuron. 2004;42:885-888.
2. Baldwin RT, Preston-Martin S. Epidemiology of brain tumors in childhood-a review. Toxicol Appl Pharmacol. 2004;199:118-131.
3. Parkin DM, Bray F, Ferlay J, et al. Global Cancer Statistics, 2002. CA. Cancer J Clin. 2005;55:74-108.
4. Armstrong TS, Cohen MZ, Eriksen LR, et al. Symptom clusters in oncology patients and implications for symptom research in people with primary brain tumors. J Nurs Scholarsh. 2004;36:197-206.
5. Behin A, Hoang-Xuan K, Carpentier AF, et al. Primary brain tumours in adults. Lancet. 2003;361:323-331.
6. Noble M, Dietrich J. The complex identity of brain tumors: emerging concerns regarding origin, diversity and plasticity. Trends Neurosci. 2004;27:148-154.
7. Mischel PS, Cloughesy TF, Nelson SF. DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat Rev Neurosci. 2004;5:782-792.
8. Giannini C, Scheithauer BW, Weaver AL, et al. Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol. 2001;60:248-262.
9. Rorke LB. Pathologic diagnosis as the gold standard. Cancer. 1997;79:665-667.
10. Lander ES. Array of hope. Nat Genet. 1999;21:3-4.
11. Ntzani EE, Ioannidis JP. Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet. 2003;362:1439-1444.
12. Segal E, Friedman N, Kaminski N, et al. From signatures to models: understanding cancer using microarrays. Nat Genet. 2005;37(suppl): S38-S45.
13. Furumoto H, Ying H, Chandramouli GV, et al. An unliganded thyroid hormone beta receptor activates the cyclin D1/cyclindependent kinase/retinoblastoma/E2F pathway and induces pituitary tumorigenesis. Mol Cell Biol. 2005;25:124-135.
14. Hui AM, Zhang W, Chen W, et al. Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells. Cancer Res. 2004;64: 9115-9123.
15. Tatenhorst L, Puttmann S, Senner V, et al. Genes associated with fast glioma cell migration in vitro and in vivo. Brain Pathol. 2005; 15:46-54.
16. Markert JM, Fuller CM, Gillespie GY, et al. Differential gene expression profiling in human brain tumors. Physiol Genomics. 2001;5:21-33.
17. Mischel PS, Shai R, Shi T, et al. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene. 2003;22: 2361-2373. (Pubitemid 36566791)
18. Nutt CL, Mani DR, Betensky RA, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 2003;63:1602-1607.
19. Watson MA, Gutmann DH, Peterson K, et al. Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays. Am J Pathol. 2002;161:665-672.
20. Liang Y, Diehn M, Watson N, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A. 2005;102:5814-5819.
21. Neben K, Korshunov A, Benner A, et al. Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res. 2004;64: 3103-3111.
22. Park PC, Taylor MD,Mainprize TG, et al. Transcriptional profiling of medulloblastoma in children. J Neurosurg. 2003;99:534-541.
23. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006; 9:157-173.
24. Tso CL, Freije WA, Day A, et al. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res. 2006;66: 159-167.
25. Freije WA, Castro-Vargas FE, Fang Z, et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 2004;64: 6503-6510.
26. Kim S, Dougherty ER, Shmulevich I, et al. Identification of combination gene sets for glioma classification. Mol Cancer Ther. 2002;1: 1229-1236.
27. Lamszus K. Meningioma pathology, genetics, and biology. J Neuropathol Exp Neurol. 2004;63:275-286.
28. Julia-Sape M, Acosta D, Majos C, et al. Comparison between neuroimaging classifications and histopathological diagnoses using an international multicenter brain tumor magnetic resonance imaging database. J Neurosurg. 2006;105:6-14.
29. Miguel PS, Fernandez G, Vasallo FJ, et al. Neurobrucellosis mimicking cerebral tumor: case report and literature review. Clin Neurol Neurosurg. 2006;108:404-406.
30. Nestler U, Schmidinger A, Schulz C, et al. Glioblastoma simultaneously present with meningioma-report of three cases. Zentralbl Neurochir. 2007;68:145-150.
31. Taillibert S, Pedretti M, Sanson M. Current classification of gliomas. Presse Med. 2004;33:1274-1277.
32. Celda B, Monleon D, Martinez-Bisbal MC, et al. MRS as endogenous molecular imaging for brain and prostate tumors: FP6 project "eTUMOR". Adv Exp Med Biol. 2006;587:285-302.
33. Patterson TA, Lobenhofer EK, Fulmer-Smentek SB, et al. Performance comparison of one-color and two-color platforms within the MicroArray Quality Control (MAQC) project. Nat Biotechnol. 2006;24:1140-1150.
34. Kleihues P, Cavenee WK. Pathology and Genetics of Tumours of the Nervous System. Lyon, France: International Agency for Research on Cancer, 2000; 2005:29-44, 176-184.
35. Tracey L, Villuendas R, Ortiz P, et al. Identification of genes involved in resistance to interferon-alpha in cutaneous T-cell lymphoma. Am J Pathol. 2002;161:1825-1837.
36. Edwards D. Non-linear normalization and background correction in one-channel cDNA microarray studies. Bioinformatics. 2003;19: 825-833.
37. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A. 2003;100:9440-9445.
38. Dennis G Jr, Sherman BT, Hosack DA, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4:3.
39. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001;25:402-408.
40. Eng LF, Ghirnikar RS, Lee YL. Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem Res. 2000;25: 1439-1451.
41. Wrobel G, Roerig P, Kokocinski F, et al. Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer. 2005;114:249-256.
42. Baba H, Nakahira K, Morita N, et al. GFAP gene expression during development of astrocyte. Dev Neurosci. 1997;19:49-57.
43. Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serumcultured cell lines. Cancer Cell. 2006;9:391-403.
44. Zhou R, Skalli O. TGF-alpha differentially regulates GFAP, vimentin, and nestin gene expression in U-373 MG glioblastoma cells: correlation with cell shape and motility. Exp Cell Res. 2000; 254:269-278.
45. Tasheva ES, Klocke B, Conrad GW. Analysis of transcriptional regulation of the small leucine rich proteoglycans. Mol Vis. 2004; 10:758-772.
46. Ge G, Seo NS, Liang X, et al. Bone morphogenetic protein-1/tolloid- related metalloproteinases process osteoglycin and enhance its ability to regulate collagen fibrillogenesis. J Biol Chem. 2004;279: 41626-41633.
47. Baharvand H, Heidari M, Ebrahimi M, et al. Proteomic analysis of epithelium-denuded human amniotic membrane as a limbal stem cell niche. Mol Vis. 2007;13:1711-1721.
48. Droguett R, Cabello-Verrugio C, Riquelme C, et al. Extracellular proteoglycans modify TGF-beta bio-availability attenuating its signaling during skeletal muscle differentiation. Matrix Biol. 2006;25: 332-341.
49. Oklu R, Hesketh R. The latent transforming growth factor beta binding protein (LTBP) family. Biochem J. 2000;352(Pt 3):601-610.
50. Purnapatre K, Khattar SK, Saini KS. Cytochrome P450s in the development of target-based anticancer drugs. Cancer Lett. 2008; 259:1-15.
51. Elexpuru-Camiruaga J, Buxton N, Kandula V, et al. Susceptibility to astrocytoma and meningioma: influence of allelism at glutathione S-transferase (GSTT1 and GSTM1) and cytochrome P-450 (CYP2D6) loci. Cancer Res. 1995;55:4237-4239.
52. Khalid MH, Tokunaga Y, Caputy AJ, et al. Inhibition of tumor growth and prolonged survival of rats with intracranial gliomas following administration of clotrimazole. J Neurosurg. 2005;103: 79-86.
53. Wundrack I, Meese E, Mullenbach R, et al. Debrisoquine hydroxylase gene polymorphism in meningioma. Acta Neuropathol. 1994;88:472-474.
54. Fiore G, Di CC, Monti G, et al. Tubulin nitration in human gliomas. Neurosci Lett. 2006;394:57-62.
55. Kim SJ, Chung TW, Jin UH, et al. Molecular mechanisms involved in transcriptional activation of the human Sia-alpha2,3-Gal-beta1, 4-GlcNAc-R: alpha2,8-sialyltransferase (hST8Sia III) gene induced by KCl in human glioblastoma cells. Biochem Biophys Res Commun. 2006;344:1057-1064.
56. Panagopoulos AT, Lancellotti CL, Veiga JC, et al. Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas. J Neurooncol. 2008;89:73-87.
57. Shimada S, Ishizawa K, Hirose T. Expression of E-cadherin and catenins in meningioma: ubiquitous expression and its irrelevance to malignancy. Pathol Int. 2005;55:1-7.
58. Barami K, Lewis-Tuffin L, Anastasiadis PZ. The role of cadherins and catenins in gliomagenesis. Neurosurg Focus. 2006;21:E13.
59. Utsuki S, Sato Y, Oka H, et al. Relationship between the expression of E-, N-cadherins and beta-catenin and tumor grade in astrocytomas. J Neurooncol. 2002;57:187-192.
60. Miles AT, Hawksworth GM, Beattie JH, et al. Induction, regulation, degradation, and biological significance of mammalian metallothioneins. Crit Rev Biochem Mol Biol. 2000;35:35-70.
61. Maier H, Jones C, Jasani B, et al. Metallothionein overexpression in human brain tumours. Acta Neuropathol (Berlin). 1997;94:599-604. (Pubitemid 27511182)
62. Altenberg B, Greulich KO. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics. 2004;84:1014-1020.
63. Kumanishi T, Watabe K, Washiyama K. An immunohistochemical study of aldolase C in normal and neoplastic nervous tissues. Acta Neuropathol (Berlin). 1985;67:309-314.
64. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891-899.
65. Gatenby RA, Gillies RJ. Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol. 2007;39:1358-1366.
66. Ulbricht U, Eckerich C, Fillbrandt R, et al. RNA interference targeting protein tyrosine phosphatase zeta/receptor-type protein tyrosine phosphatase beta suppresses glioblastoma growth in vitro and in vivo. J Neurochem. 2006;98:1497-1506.
67. Muller S, Lamszus K, Nikolich K, et al. Receptor protein tyrosine phosphatase zeta as a therapeutic target for glioblastoma therapy. Expert Opin Ther Targets. 2004;8:211-220.
68. Pushkin A, Abuladze N, Gross E, et al. Molecular mechanism of kNBC1-carbonic anhydrase II interaction in proximal tubule cells. J Physiol. 2004;559:55-65.
69. Haapasalo JA, Nordfors KM, Hilvo M, et al. Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res. 2006;12:473-477.